- Home
- BTAI vs MARPS Comparison
BTAI vs MARPS Comparison
Compare BTAI & MARPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MARPS
- Stock Information
- Founded
- BTAI 2017
- MARPS 1956
- Country
- BTAI United States
- MARPS United States
- Employees
- BTAI N/A
- MARPS N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MARPS Oil & Gas Production
- Sector
- BTAI Health Care
- MARPS Energy
- Exchange
- BTAI Nasdaq
- MARPS Nasdaq
- Market Cap
- BTAI 8.3M
- MARPS 7.5M
- IPO Year
- BTAI 2018
- MARPS N/A
- Fundamental
- Price
- BTAI $1.86
- MARPS $4.54
- Analyst Decision
- BTAI Buy
- MARPS
- Analyst Count
- BTAI 5
- MARPS 0
- Target Price
- BTAI $34.60
- MARPS N/A
- AVG Volume (30 Days)
- BTAI 295.5K
- MARPS 246.6K
- Earning Date
- BTAI 08-05-2025
- MARPS 01-01-0001
- Dividend Yield
- BTAI N/A
- MARPS 7.84%
- EPS Growth
- BTAI N/A
- MARPS N/A
- EPS
- BTAI N/A
- MARPS 0.36
- Revenue
- BTAI $1,852,000.00
- MARPS $1,036,019.00
- Revenue This Year
- BTAI $5.03
- MARPS N/A
- Revenue Next Year
- BTAI $291.01
- MARPS N/A
- P/E Ratio
- BTAI N/A
- MARPS $12.44
- Revenue Growth
- BTAI 5.47
- MARPS N/A
- 52 Week Low
- BTAI $1.17
- MARPS $3.34
- 52 Week High
- BTAI $21.92
- MARPS $7.90
- Technical
- Relative Strength Index (RSI)
- BTAI 56.60
- MARPS 52.35
- Support Level
- BTAI $1.69
- MARPS $4.21
- Resistance Level
- BTAI $2.08
- MARPS $4.83
- Average True Range (ATR)
- BTAI 0.21
- MARPS 0.93
- MACD
- BTAI 0.02
- MARPS -0.08
- Stochastic Oscillator
- BTAI 57.89
- MARPS 21.65
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.